Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
Co-Diagnostics (Nasdaq: CODX) announced the formation of a new artificial intelligence business unit, led by Chief Technology & AI Officer Christopher Thurston, to consolidate the company’s AI initiatives into the Co-Dx Primer Ai platform.
The company said the unit aims to accelerate development of proprietary AI-powered PCR diagnostics, support Co-Primers design and workflow orchestration, enable automated test interpretation, and integrate analytics via a HIPAA-compliant Co-Dx cloud. The release notes the Co-Dx PCR platform remains subject to FDA and other regulatory review and is not available for sale.
Co-Diagnostics (Nasdaq: CODX) ha annunciato la creazione di una nuova unità di business di intelligenza artificiale, guidata dal Chief Technology & AI Officer Christopher Thurston, per consolidare le iniziative IA dell’azienda nella piattaforma Co-Dx Primer Ai.
L’azienda ha dichiarato che l’unità punta ad accelerare lo sviluppo di diagnostici PCR proprietari basati sull’IA, a supportare la progettazione di Co-Primers e l’orchestrazione del flusso di lavoro, a consentire l’interpretazione automatizzata dei test e a integrare analisi tramite un cloud Co-Dx conforme a HIPAA. Il comunicato indica che la piattaforma Co-Dx PCR resta soggetta a revisione da parte della FDA e di altre autorità regolatorie e non è disponibile per la vendita.
Co-Diagnostics (Nasdaq: CODX) anunció la creación de una nueva unidad de negocio de inteligencia artificial, liderada por el Director de Tecnología e IA Christopher Thurston, para consolidar las iniciativas de IA de la empresa en la plataforma Co-Dx Primer Ai.
La empresa indicó que la unidad tiene como objetivo acelerar el desarrollo de diagnósticos PCR impulsados por IA propietarios, apoyar el diseño de Co-Primers y la orquestación del flujo de trabajo, habilitar la interpretación automatizada de pruebas e incorporar analítica a través de un cloud Co-Dx que cumpla con HIPAA. El comunicado señala que la plataforma Co-Dx PCR sigue estando sujeta a revisión por la FDA y otras autoridades regulatorias y no está disponible para la venta.
Co-Diagnostics (Nasdaq: CODX)은 새로운 인공지능 사업 부문을 설립했다고 발표했습니다. 이 부문은 최고 기술 및 AI 책임자 Christopher Thurston이 이끌며, 회사의 AI 이니셔티브를 Co-Dx Primer Ai 플랫폼으로 통합하기 위한 것입니다.
회사에 따르면 이 부문의 목표는 독점적인 AI 기반 PCR 진단의 개발을 가속하고, Co-Primers 설계 및 워크플로우 오케스트레이션을 지원하며, 테스트 해석의 자동화를 가능하게 하고, HIPAA 준수 Co-Dx 클라우드를 통해 분석을 통합하는 것이라고 합니다. 보도자료에 따르면 Co-Dx PCR 플랫폼은 FDA 및 기타 규제 심사 대상이며 판매용이 아닙니다.
Co-Diagnostics (Nasdaq: CODX) a annoncé la création d'une nouvelle unité commerciale dédiée à l'intelligence artificielle, dirigée par le Chief Technology & AI Officer Christopher Thurston, afin de réunir les initiatives IA de l'entreprise sur la plateforme Co-Dx Primer Ai.
L'entreprise précise que l'unité vise à accélérer le développement de diagnostics PCR propulsés par l'IA propriétaires, à soutenir la conception de Co-Primers et l'orchestration des flux de travail, à permettre l'interprétation automatisée des tests et à intégrer l'analytique via un cloud Co-Dx conforme HIPAA. Le communiqué indique que la plateforme Co-Dx PCR demeure soumise à l'examen de la FDA et d'autres autorités réglementaires et n'est pas disponible à la vente.
Co-Diagnostics (Nasdaq: CODX) hat die Bildung einer neuen Geschäfts-einheit für Künstliche Intelligenz angekündigt, geleitet vom Chief Technology & AI Officer Christopher Thurston, um die KI-Initiativen des Unternehmens in der Plattform Co-Dx Primer Ai zu konsolidieren.
Das Unternehmen erklärte, dass die Einheit darauf abzielt, die Entwicklung proprietärer KI-basierter PCR-Diagnostika zu beschleunigen, das Design von Co-Primers und die Workflow-Orchestrierung zu unterstützen, eine automatisierte Testinterpretation zu ermöglichen und Analytik über eine HIPAA-konforme Co-Dx-Cloud zu integrieren. Die Mitteilung stellt fest, dass die Co-Dx PCR-Plattform weiterhin der FDA- und anderen behördlichen Prüfungen unterliegt und nicht zum Verkauf steht.
Co-Diagnostics (Nasdaq: CODX) أعلنت عن تشكيل وحدة أعمال جديدة للذكاء الاصطناعي، بقيادة رئيس التكنولوجيا والذكاء الاصطناعي Christopher Thurston، وذلك لدمج مبادرات الشركة في الذكاء الاصطناعي ضمن منصة Co-Dx Primer Ai.
وقالت الشركة إن الوحدة تهدف إلى تسريع تطوير تشخيصات PCR المعتمدة على الذكاء الاصطناعي، ودعم تصميم Co-Primers وتنظيم تدفقات العمل، وتمكين تفسير الاختبارات تلقائياً، ودمج التحليلات عبر سحابة Co-Dx متوافقة مع HIPAA. وتذكر البيان أن منصة Co-Dx PCR لا تزال خاضعة للمراجعة من قِبل FDA والجهات التنظيمية الأخرى وليست متاحة للبيع.
- None.
- None.
Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx's existing and future AI initiatives
Co-Dx anticipates that allocating resources to the newly formed AI business unit will enable the Company to develop proprietary AI-powered diagnostics more efficiently and reduce time-to-market for new tests. The Company also believes that future AI tools will be able to leverage the analytics yielded from widespread deployment and commercialization of the Co-Dx PCR Pro* to improve situational awareness during a health crisis, and potentially predict outbreaks and pandemics before they occur.
"Since our founding in 2013, Co-Diagnostics has been at the forefront of PCR technology innovation, beginning with the introduction of the revolutionary Co-Primers® technology, and later with the development of the Co-Dx PCR platform to help close the diagnostics access gap," remarked Dwight Egan, Co-Dx Chief Executive Officer. "Now, as the rate of adoption of enterprise artificial intelligence increases and AI applications continue to grow in ubiquity and utility, we have begun incorporating these next-generation tools to help increase operational efficiency, minimize human error, improve outcomes in real-time point-of-care testing, and truly give physicians, patients, and communities the Power to Know™."
The Company's next-generation diagnostics technology, enhanced by proprietary AI models, enables real-time PCR diagnostics at the point-of-care. Co-Dx's AI models support internal data and workflow orchestration, as well as Co-Primers design and optimization. Future models will enhance automated test interpretation and create predictive epidemiological awareness. These models will operate in tandem with the Company's HIPAA-compliant Co-Dx cloud platform and internal databases to form the foundation of Co-Dx Primer Ai.
*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the Company's expectations that the formation of its AI business unit will enable more efficient development of proprietary AI-powered diagnostics, improve situational awareness, and reduce time-to-market for new tests; the belief that future AI tools and models will leverage analytics from deployment of the Co-Dx PCR Pro™ platform to improve outbreak prediction and real-time awareness; anticipated benefits of incorporating next-generation AI tools to increase operational efficiency, minimize human error, and improve point-of-care outcomes; and expectations regarding future regulatory review and potential commercialization of the Co-Dx PCR platform and related products.. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 27, 2025, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-to-integrate-and-implement-proprietary-artificial-intelligence-technology-into-co-dx-primer-ai-platform-302602287.html
SOURCE Co-Diagnostics
FAQ
What did Co-Diagnostics (CODX) announce on November 3, 2025?
Who will lead Co-Diagnostics' new AI business unit at CODX?
How will CODX use AI in the Co-Dx Primer Ai platform?
Does Co-Dx PCR Pro and related CODX products have FDA clearance for sale?
What compliance does Co-Diagnostics cite for Co-Dx Primer Ai at CODX?
What operational benefits does CODX expect from the new AI unit?
